GSK (GSK) has agreed to acquire Boston Pharmaceuticals' investigational steatotic liver disease treatment efimosfermin alfa for up to $2 billion in cash, the companies said Wednesday.
The company will pay $1.2 billion upfront, with potential for certain additional milestone payments amounting to $800 million. Under the terms of the deal, GSK will buy Boston Pharmaceuticals unit BP Asset IX to access efimosfermin.
GSK will be responsible for success-based milestone payments, as well as tiered royalties for efimosfermin owed to Novartis Pharma, the companies said.
GSK shares were up 2.1% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。